Intellia Therapeutics is a biopharmaceutical company focused on CRISPR-based gene editing therapies. Its lead product candidates are lonvoguran ziclumeran (lonvo-z, NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (nex-z, NTLA-2001) for transthyretin amyloidosis, both in Phase 3 development. The company leverages proprietary CRISPR, lipid nanoparticle (LNP), and oligonucleotide technologies to develop in vivo genome editing treatments administered as a single IV infusion, with a planned commercial launch of lonvo-z in the first half of 2027.
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076550 | EDGAR | 95K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029007 | EDGAR | 95K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018736 | EDGAR | 99K words |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004097 | EDGAR | 101K words |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001981 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001564590-21-009011 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007409 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004680 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001564590-18-005544 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001193125-17-082186 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-337952 | EDGAR | 59K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269680 | EDGAR | 62K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104987 | EDGAR | 60K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066914 | EDGAR | 56K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123276 | EDGAR | 58K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093907 | EDGAR | 57K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057046 | EDGAR | 54K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062011 | EDGAR | 61K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037996 | EDGAR | 60K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017866 | EDGAR | 56K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021835 | EDGAR | 67K words |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014731 | EDGAR | 65K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001193125-26-385194 | EDGAR | 1K words |
| 2026-09-04 | 0001193125-26-383645 | EDGAR | 1K words |
| 2026-08-06 | 0001193125-26-336772 | EDGAR | 3K words |
| 2026-03-02 | 0001193125-26-084309 | EDGAR | 2K words |
| 2026-02-26 | 0001193125-26-073456 | EDGAR | 3K words |
| 2026-01-27 | 0001193125-26-023387 | EDGAR | 1K words |
| 2026-01-09 | 0001193125-26-008307 | EDGAR | 6K words |
| 2025-11-10 | 0001193125-25-274596 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-269479 | EDGAR | 3K words |
| 2025-10-29 | 0001193125-25-256378 | EDGAR | 1K words |
204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001652130 |
| Ticker | NTLA |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.intelliatx.com |
| Listed | 2016-05-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NTLA (~200 tokens, structured JSON with cryptographic provenance)